Hexarelin Peptide Improves Heart Failure in Rats by Modulating PTEN Pathway
Background
Heart failure is a severe condition where the heart struggles to pump enough blood, often resulting from ischemic heart disease like that caused by a heart attack. Coronary artery ligation is a standard surgical procedure used in animal models to mimic this damage and induce heart failure. The PTEN (Phosphatase and tensin homolog) pathway is a critical regulator of cell growth, survival, and metabolism, and its dysregulation contributes significantly to cardiac remodeling and dysfunction post-injury. This study addresses the knowledge gap regarding how hexarelin, a synthetic growth hormone secretagogue, might modulate PTEN to protect the heart and mitigate heart failure progression.
Results
Treatment with hexarelin significantly preserved cardiac function and attenuated adverse remodeling in the heart failure model. Echocardiography revealed that hexarelin-treated rats exhibited a 35% improvement in left ventricular ejection fraction (LVEF) compared to controls (45% vs 33%, p<0.01). Cardiac remodeling was also markedly reduced, with a 28% decrease in left ventricular end-diastolic diameter (LVEDD) and a 22% reduction in left ventricular end-systolic diameter (LVESD) in the hexarelin group compared to controls (p<0.05). > The study's most critical finding was that hexarelin treatment led to a 2.5-fold increase in Akt phosphorylation and a 1.8-fold increase in ERK phosphorylation, alongside a 40% reduction in PTEN expression in cardiac tissue, indicating robust activation of pro-survival and anti-apoptotic pathways. Furthermore, hexarelin significantly reduced myocardial fibrosis by 43% and cardiomyocyte apoptosis by 38% compared to the control group (p<0.001 for both).
Why It Matters
This study provides compelling evidence for hexarelin's potential as a novel therapeutic agent for ischemic heart failure by beneficially modulating the PTEN/Akt/ERK signaling pathway. The observed significant improvements in cardiac function, reduced remodeling, and activation of pro-survival pathways suggest a promising new strategy to protect the heart following injury. These robust preclinical findings strongly support the further investigation of hexarelin for treating human heart failure, potentially leading to new clinical applications and improved patient outcomes. Future research should focus on detailed dose-response studies, long-term safety profiles, and ultimately, progression to human clinical trials (Phase I/II) to translate these promising results.